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Abstract 21 
Nonmedical prescription opioid use (NMPOU) has increased alarmingly across 22 
Canada and resulted in strict prescribing restrictions on opioids. Despite a clear need to 23 
reduce opioid prescriptions in response to this crisis, few other policies have been 24 
implemented and this singular focus is incongruent with the known characteristics of 25 
substance use disorders, negative effects of supply reduction policies, and realities of 26 
pain management. Given the recent rise of Fentanyl and other dangerous adulterants in 27 
street drugs, this commentary argues that a comprehensive response to NMPOU that 28 
includes improvements to addiction management and harm-reduction services is 29 
urgently needed.  30 
MeSH keywords: Public health; pain; opioid-related disorder; harm reduction 31 
Text 32 
Nonmedical prescription opioid use (NMPOU) has created widespread public 33 
health problems across North America, as well as challenges for physicians and policy-34 
makers alike. Recommendations for addressing NMPOU have focused primarily on 35 
restricting opioid prescribing to reduce iatrogenic dependency, NMPOU incidence, and 36 
prescription opioid (PO) diversion;1, 2 however, broader policies to prevent and reduce 37 
the harms of NMPOU are lacking. Despite the clear need to reduce opioid prescribing, 38 
the singular focus of this response is incongruent with the known characteristics of 39 
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substance use disorders, negative effects of supply reduction policies, and realities of 40 
pain management. While safe prescribing practices that reduce PO diversion and 41 
NMPOU incidence should be promoted, the recent use of Fentanyl and other dangerous 42 
adulterants, such as Carfentanyl, in street drugs heightens the need for a 43 
comprehensive public health response that addresses substance use more widely. 44 
Consequently, we argue that it is reasonable to foresee negative consequences such as 45 
Fentanyl-related overdoses arising from constraining the supply of POs without also 46 
addressing policy deficiencies related to managing substance use disorders and pain. 47 
A long-standing body of scientific literature characterizes problematic substance 48 
use as a chronic and relapsing neurobiological disorder3 that is exacerbated by social 49 
and economic deprivations.4 Despite this knowledge, stigma and misconceptions of 50 
addiction endure among some healthcare professionals which affects the quality of care 51 
for patients with substance use disorders.5 In addition, the evidence-practice gap has 52 
resulted in morality-based law enforcement strategies that remain the predominant 53 
response to substance use and repeatedly fail to achieve meaningful progress.  54 
Although the failing “war on drugs” has consistently demonstrated that supply 55 
reduction policies often result in perverse unintended consequences that severely 56 
undermine public health and safety, the principles of supply reduction are being 57 
expanded to opioid prescribing in numerous jurisdictions in order to prevent the 58 
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initiation of NMPOU and diversion of POs. Given the powerful withdrawal symptoms 59 
and cravings associated with opioid use disorders, however, prescribing restrictions 60 
may not have the intended effect among those who experience these symptoms and are 61 
compelled to seek out relief. Individuals who cannot acquire POs due to limited 62 
availability or cannot use POs via their preferred route of administration due to abuse 63 
deterrent formulations may resort to a substitute drug; indeed, research findings link 64 
PO supply reduction measures in the United States with transitions from POs to street 65 
drugs such as heroin among some at-risk groups.6, 7 In an era of increasing adulteration 66 
of street drugs with Fentanyl, related analogues, and new synthetic chemicals these 67 
risks are particularly concerning. 68 
Although POs are only effective for treating certain types of pain,8 the issue of 69 
pain management is entwined with NMPOU given that those who engage in NMPOU 70 
frequently report pain relief as a motivation for use.9 However, current prescribing 71 
guidelines recommend non-pharmacological therapies for treating pain which many 72 
healthcare systems are not equipped to provide or require substantial out-of-pocket 73 
expenses.8 In addition, research on the benefits of medical cannabis is lagging despite 74 
the potential for medical cannabis to be substituted for PO use10 and decrease PO-75 
related emergency room admissions.11 Consequently, sanctioned pain treatment can be 76 
very difficult to access, and this disproportionately affects at-risk groups such as older 77 
adults and those who have low incomes. This paradox is consistent with the inverse 78 
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care law, where people who are most vulnerable and in need of healthcare services are 79 
less likely to receive adequate healthcare than the general population.  80 
Considering the well-established characteristics of substance use disorders, 81 
harms associated with supply reduction policies, and importance of effectively 82 
managing pain, the current policy focus on restricting POs is too narrow. In addition to 83 
these restrictions that reduce NMPOU incidence and PO diversion, parallel efforts to 84 
care for those already engaging in NMPOU are critical for avoiding the unintentional 85 
consequences of decreasing the supply of POs and increasing risk of exposure to 86 
adulterated street drugs. A comprehensive approach to NMPOU is needed that 87 
addresses the realities of both the NMPOU epidemic and substance use disorders, and 88 
introduces policy reforms that improve access to non-pharmacological pain treatments. 89 
These broader policy solutions may include physician-specific policies and scaling-up 90 
evidence-based harm reduction services. 91 
To address NMPOU, physicians should use prescription drug monitoring 92 
databases and safe prescribing practices, such as urine drug screen tests and treatment 93 
agreements. Physicians who learn of patients engaging in NMPOU, however, should 94 
continue providing the best medical care for those patients instead of immediately 95 
discontinuing POs. Regimen noncompliance or NMPOU should trigger an 96 
intensification of services for these patients, which may include assistance tapering off 97 
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POs, and facilitating access to opioid agonist treatment and other harm reduction 98 
services as appropriate. Heroin-assisted treatment programs are also feasible for 99 
treating individuals who do not respond to traditional opioid agonist treatment 100 
therapies and require higher treatment intensity.12 In addition, emergency department 101 
protocols for managing opioid withdrawal may provide an important entry point for 102 
engaging patients who use POs nonmedically in care. Although innovative solutions 103 
such as these are necessary for addressing NMPOU, novel programs or policies often 104 
lack expansive evidence bases to guide implementation in new settings. There is 105 
considerable evidence, however, affirming addiction as as chronic and relapsing 106 
medical condition that requires long-term treatment13 and wraparound services.14  107 
Efforts to reduce enduring barriers to opioid agonist treatment and expand other 108 
programs with strong evidence bases, such as drug consumption rooms, drug testing 109 
services, needle exchanges, and naloxone distribution, are also important. Despite 110 
numerous challenges to implement successfully,15 harm reduction strategies are 111 
effective in many settings for helping people with substance use disorders maintain 112 
engagement with healthcare services, reduce potential harms such as fatal overdoses, 113 
and facilitate linkages to other services, including treatment. This approach has been 114 
successful precisely because it addresses the realities of substance use disorders without 115 
moralizing or stigma. Unfortunately, these programs are largely absent from 116 
mainstream healthcare and remain chronically under-funded as services for a relatively 117 
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small and marginalized section of the population. The ubiquity of NMPOU and the rise 118 
of Fentanyl, however, expose the need to better integrate harm reduction services 119 
within healthcare systems, expand anti-poverty programs, reduce addiction-related 120 
stigma among healthcare professionals, and give serious consideration to 121 
decriminalizing or legalizing all illicit drugs.  122 
It is clear that physicians who prescribe and do not prescribe POs are caught in 123 
ethical dilemmas where they risk “doing harm” regardless of their decision. Despite a 124 
clear need to reduce PO prescriptions, comparable attention to closing the evidence-125 
practice gap and implementing a comprehensive response to NMPOU beyond supply-126 
reducing efforts is important. Given the realities of substance use disorders and 127 
emergence of Fentanyl and dangerous adulterants in street drugs , broader policy 128 
solutions will reduce the risk of pushing vulnerable citizens further to the margins and 129 
provide a meaningful response to this epidemic. 130 
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